NCT/Study#

MGD019-01

?A Phase 1, First-in-Human, Open- Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms? (the ?Study?).

?A Phase 1, First-in-Human, Open-
Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in
Patients with Unresectable or Metastatic Neoplasms? (the ?Study?).

DISEASE GROUP:
Phase 1
current phase:
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: